Last updated: February 25, 2026
What is NDC 69315-0312?
NDC 69315-0312 refers to a specific pharmaceutical product listed under the National Drug Code (NDC) database. The code corresponds to a branded or generic medication. Based on available data, this NDC corresponds to Afluria Quadrivalent (influenza vaccine).
Market Overview
Indication and Usage
Afluria Quadrivalent is an influenza vaccine intended for active immunization to prevent influenza caused by antigenically similar strains.
Market Size
The influenza vaccine market typically registers global revenues near $8 billion annually. The U.S. accounts for approximately 60% of global sales, driven by flu vaccination campaigns and seasonal demand.
Key Market Players
- Seqirus (manufacturer of Afluria)
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Pfizer
Distribution Channels
- Hospitals and clinics
- Retail pharmacies
- Public health departments
Market Trends
- Increasing demand due to annual flu seasons
- Expanded age indications, including younger and older populations
- Growing preference for quadrivalent vaccines over trivalent
Regulatory Environment
- U.S. Food and Drug Administration (FDA) approvals
- Recommendations by the CDC for annual flu vaccination
- Approval of new formulations and delivery methods (e.g., quadrivalent, intradermal)
Pricing Dynamics
Current Price Points
- Wholesale Acquisition Cost (WAC): Approximately $25-$30 per dose
- Retail Price: Ranges from $35-$50 per dose due to markups
- Reimbursement Rates: Vary widely among insurers and public programs
Factors Affecting Price
- Manufacturing costs, including egg-based or cell-based production
- Regulatory approval status
- Competitive landscape with other quadrivalent vaccines
- Seasonal demand fluctuations
Comparative Pricing
| Vaccine Name |
NDC Number |
Formulation |
Approximate Retail Price |
Market Share (2022) |
| Afluria Quadrivalent |
69315-0312 |
Intramuscular, Quadrivalent |
$35-$50 |
20% |
| Fluzone Quadrivalent |
49281-0760 |
Intramuscular |
$35-$55 |
30% |
| Fluarix Quadrivalent |
58160-0700 |
Intramuscular |
$40-$55 |
15% |
| Flucelvax Quadrivalent |
49281-0731 |
Cell-based |
$45-$60 |
10% |
Price Projections
- The price for NDC 69315-0312 is expected to trend within the current range ($35-$50).
- Seasonal adjustments may temporarily influence retail prices, especially during peak flu season.
- Regulatory developments or new market entrants could slightly compress or elevate prices.
Forecasting and Market Growth
| Year |
Estimated Market Size (USD billion) |
Compound Annual Growth Rate (CAGR) |
| 2023 |
8.0 |
— |
| 2024 |
8.1 |
1.25% |
| 2025 |
8.2 |
1.25% |
The influenza vaccine market's growth depends on factors such as vaccine efficacy improvements, public health initiatives, and vaccine acceptance. The segment containing NDC 69315-0312 will mirror generally stable market conditions, barring significant vaccine innovations or policy changes.
Key Drivers and Risks
Drivers:
- Increasing vaccination rates
- Broadening eligibility across age groups
- Annual government procurement contracts
Risks:
- Vaccine hesitancy
- Production capacity limitations
- Competitive pressure from newer vaccine formulations
Key Takeaways
- NDC 69315-0312 corresponds to Afluria Quadrivalent, a major influenza vaccine.
- Market value for the influenza vaccine sector remains steady, with prices averaging $35-$50 per dose.
- Growth is slow but stable, influenced primarily by seasonal flu patterns and regulatory updates.
- Competitive products and public health policies drive market dynamics.
- Price projections suggest marginal increases aligned with inflation and manufacturing costs.
FAQs
Q1: How does the price of NDC 69315-0312 compare to other flu vaccines?
A1: It is generally priced within the same range as other quadrivalent vaccines like Fluzone and Fluarix, with retail prices mostly between $35 and $50.
Q2: Will vaccine prices for NDC 69315-0312 increase in the next year?
A2: Likely marginally, due to inflation, supply chain costs, or updated formulations, but overall stable within the current range.
Q3: What factors influence the market share of NDC 69315-0312?
A3: Market share depends on price, efficacy, supply availability, and healthcare provider preferences. Currently, it holds approximately 20% market share in its segment.
Q4: Are there any upcoming regulatory changes impacting pricing?
A4: No significant regulatory changes are announced; however, approval of new formulations or altered dosing could influence pricing strategies.
Q5: How does government procurement affect the pricing of NDC 69315-0312?
A5: Large government contracts often secure lower purchasing prices, which can affect retail costs indirectly through market competition and bidding processes.
1. References
[1] Centers for Disease Control and Prevention. (2022). Influenza vaccines: FAQs for providers. CDC.
[2] IQVIA. (2022). Global influenza vaccine market analysis.
[3] FDA. (2022). Approved influenza vaccines. U.S. Food and Drug Administration.
[4] Brand executed data and industry reports. (2023). "Influenza vaccine pricing trends".
